Telescope InnovationsTELIF -0.93%31 PB Ratio is 17.10 as of Jul. 01, 2026, which is 117% above its 10-year median of 7.89. GuruFocus rates TELIF with a GF Score™ of 31/100 and a GF Value™ of $0.38 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 1,229 Biotechnology companies, Telescope Innovations ranks worse than 92.35% on this metric.
The historical rank and industry rank for Telescope Innovations's PB Ratio or its related term are showing as below:
TELIF'
s PB Ratio Range Over the Past 10 Years
Min: 2.64 Med: 7.89 Max: 160
Current: 17.67
During the past 7 years, Telescope Innovations's highest PB Ratio was 160.00. The lowest was 2.64. And the median was 7.89.
TELIF's PB Ratio is ranked worse than 92.35% of 1229
companies
in the Biotechnology industry
Industry Median: 2.87
vs TELIF: 17.67
During the past 12 months, Telescope Innovations's average Book Value Per Share Growth Rate was 1300.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 2.90% per year.
During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Telescope Innovations was 2.90% per year. The lowest was -29.50% per year. And the median was -13.30% per year.
Back to Basics: PB Ratio
Telescope Innovations (OTCPK:TELIF) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Telescope Innovations's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Telescope Innovations PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Telescope Innovations's PB Ratio distribution charts can be found below:
* The bar in red indicates where Telescope Innovations's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Telescope Innovations (TELIF) has a PB Ratio of 17.10 as of Jul. 01, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Telescope Innovations and its competitors. This is 117% above median its historical median of 7.89. Over the past decade, Telescope Innovations' PB Ratio has ranged from 2.64 to 160.00. According to the industry distribution chart, Telescope Innovations ranks #1135 out of 1229 companies in the Biotechnology industry, placing it in the top 92.4%.
Is Telescope Innovations' PB Ratio too high?
Telescope Innovations' current PB Ratio of 17.10 is 117% above median its 10-year median of 7.89. Over the past 10 years, this metric has ranged from a low of 2.64 to a high of 160.00. The Biotechnology industry median PB Ratio is 2.87. Telescope Innovations' value of 17.10 is 495.8% above this industry median. Based on the distribution chart, Telescope Innovations ranks #1135 out of 1229 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Telescope Innovations has a GF Score™ of 31/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Telescope Innovations' PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Telescope Innovations ranks #1135 out of 1229 companies for PB Ratio. This places Telescope Innovations in the lower half of its industry. The industry median PB Ratio is 2.87. Telescope Innovations' value of 17.10 is 495.8% above this benchmark. Historically, Telescope Innovations' own PB Ratio has ranged from 2.64 to 160.00 over the past decade. While the company's 10-year median is 7.89 vs. the industry median of 2.87, Telescope Innovations has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.87, based on 1,229 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Telescope Innovations's current PB Ratio of 17.10 is 495.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Telescope Innovations and its competitors. For the Biotechnology industry, the median PB Ratio is 2.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Telescope Innovations's current PB Ratio is 17.10, which is 117% above median its own 10-year median of 7.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Telescope Innovations stock overvalued right now?
Based on GuruFocus' analysis, Telescope Innovations (TELIF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.38, compared to a current price of $0.53 — trading 39.5% above its estimated fair value. The current PB Ratio is 17.10, which is 117% above median its 10-year median of 7.89 and 495.8% above the Biotechnology industry median of 2.87. Telescope Innovations' overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Telescope Innovations (TELIF), the current PB Ratio is 17.10 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Telescope Innovations (TELIF) Overvalued in 2026?
Based on GuruFocus' analysis, Telescope Innovations stock appears to be overvalued.
The current stock price of $0.53 is trading 39.5% above its estimated GF Value™ of $0.38.
GuruFocus considers Telescope Innovations to be Significantly Overvalued.
Key valuation signals for TELIF:
PB Ratio: 17.10 (117% above median its 10-year median of 7.89)
GF Value™: $0.38 vs. price of $0.53 (39.5% above fair value)
Industry Position: 495.8% above the Biotechnology median (#1135 of 1229)
No single metric tells the full story. See the TELIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Telescope Innovations Corp is a technology company focused on development as a Contract Research Organization (CRO) to develop intellectual property, provide contract research, and build automation products, and operates as a chemical technology company developing scalable manufacturing processes and tools for the pharmaceutical and chemical industry. Its flagship product is the DirectInject-LC system. The Company operates in a single operating segment and generates revenue from three streams: contract research services, grant income, and the sale of automation products, with the majority of revenue derived from automation product sales from customer contracts. It operates in Canada, the United States, Europe, and Asia, with the majority of revenue coming from the United States.
31GF Score
Get the complete analysis for TELIF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TELIF has been successfully added to your 
